Current progress in innovative engineered antibodies.

Area of Science:

• Biologics and Therapeutic Antibodies
• Drug Development and Clinical Trials
• Immunotherapy and Oncology

Background:

• As of May 2017, 74 antibody-based drugs were approved, with 719 in clinical development.
• The pipeline includes naked IgGs, antibody-drug conjugates, bispecific antibodies, and fusion proteins.
• Ongoing research explores novel antibody applications and delivery systems.

Purpose of the Study:

• To provide a comprehensive overview of the current landscape of antibody-based biologics in clinical development.
• To highlight the diversity in antibody formats and therapeutic targets, particularly in oncology.
• To discuss advancements in delivery methods for antibody-based therapies.

Main Methods:

• Analysis of regulatory approvals and clinical trial data for antibody-based molecules.
• Categorization of antibody-based candidates by type (e.g., IgG, ADC, bispecific) and clinical phase.
• Review of emerging therapeutic strategies, including T-cell modulation and novel delivery routes.

Main Results:

• A total of 719 antibody-based molecules were in clinical trials, encompassing various formats.
• Over 250 T-cell interacting antibody-based candidates are in development for oncology.
• Significant progress reported in blood-brain barrier, oral, intracellular, and gene/viral delivery methods.

Conclusions:

• At least 864 antibody-based clinical-stage molecules or cells are under investigation.
• The field is characterized by remarkable innovation in molecular design and therapeutic application.
• Antibody-based biologics offer diverse and promising approaches to address unmet medical needs.